Clinical trials: Heart Failure, Reduced Ejection Fraction
Non-Ischemic Heart Failure, Reduced Ejection Fraction Heart Failure
ASCs in Recently Diagnosed Non-ischemic Heart Failure
The goal of this clinical trial is to investigate the efficacy and safety of intravenous infusions of allogeneic adipose tissue-derived mesechymal stromal cells in patients with recently diagnosed non-ischemic heart failure in…
- Trial name
- ARIISE (NCT06840275)
- Testing
- Allogeneic adipose tissue-derived mesenchymal stem cells, Cryostor CS10
- Where
- Denmark
- Sponsor
- Cell to Cure ApS
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Beta 3 Agonist Treatment in Heart Failure
Objective: The objective of the study is to assess the structural and functional cardiac effects of treatment with the beta 3 AR agonist Mirabegron in patients with chronic heart failure.
- Trial name
- Beat-HF (NCT01876433)
- Testing
- Mirabegron
- Where
- 3 sites in Australia, Denmark
- Volunteers
- 70 people
- Sponsor
- Henning Bundgaard
Heart Failure
Multiple Dose Study in Heart Failure of BAY 1067197
This is a study to investigate the safety, tolerability and early effects on cardiac function of the partial A1 agonist BAY1067197 in patients with chronic heart failure.
- Trial name
- PARSiFAL (NCT02040233)
- Testing
- BAY1067197 (10 mg), BAY1067197
- Where
- 6 sites in Germany, Italy and 2 more
- Volunteers
- 31 people
- Sponsor
- Bayer
Heart Failure, Heart Failure With Reduced Ejection Fraction
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure…
- Trial name
- COMET-HF (NCT06736574)
- Testing
- Omecamtiv Mecarbil (OM)
- Where
- 209 sites in United States, Canada and 8 more
- Volunteers
- 1,800 people
- Sponsor
- Cytokinetics
Heart Failure With Reduced Ejection Fraction
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =< 35%).
- Trial name
- PARADIGM-HF (NCT01035255)
- Testing
- LCZ696 200 mg BID, Enalapril 10 mg BID
- Where
- 1,031 sites in United States, Argentina and 45 more
- Volunteers
- 8,442 people
- Sponsor
- Novartis Pharmaceuticals
Atrial Fibrillation (AF), Heart Failure With Mildly Reduced Ejection Fraction
Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication
This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function.
- Conditions
- Atrial Fibrillation (AF), Heart Failure With Mildly Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction (HFPEF), Rate Control
- Trial name
- NCT07272902
- Testing
- Catheter Ablation for Atrial Fibrillation, Rate Control Medications (beta-blockers, calcium channel blockers, digoxin)
- Where
- 4 sites in Canada
- Volunteers
- 84 people
- Sponsor
- Nova Scotia Health Authority
Heart Failure and Reduced Ejection Fraction, Dyssynchrony
Comparing Three Types of Specialist Pacemakers to Improve Heart Function and Reduce Rhythm Problems in Heart Failure
The goal of this clinical trial is to find out which type of specialist pacemaker-known as cardiac resynchronisation therapy (CRT)-works best for people with heart failure and a delay in how the lower chambers of the heart beat…
- Trial name
- RIPCORD-CRT (NCT07430553)
- Testing
- Biventricular pacing, Conduction system pacing, Left bundle optimised cardiac resynchronisation therapy
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Imperial College London
Heart Failure, Hyperkalemia
OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure
Mineralocorticoid receptor antagonists (MRA) is one of cornerstones in the treatment of heart failure with reduced ejection fraction (HFrEF). However, MRA has been extremely under-used globally.
- Trial name
- OPRA-HF (NCT04789239)
- Testing
- Sodium zirconium cyclosilicate
- Where
- 2 sites in Sweden
- Volunteers
- 110 people
- Sponsor
- Michael Fu
Heart Failure, Pleural Effusion
Thoracentesis to Alleviate Cardiac Pleural Effusion
The present study will examine the comparative effectiveness of two treatment strategies currently used in the treatment of patients with systolic heart failure presenting with pleural effusion.
- Trial name
- TAP-IT (NCT05017753)
- Testing
- Thoracentesis, Standard-of-care medical treatment
- Where
- 10 sites in Denmark
- Volunteers
- 135 people
- Sponsor
- Bispebjerg Hospital
Frailty Syndrome, Heart Failure and Mildly Reduced Ejection Fraction
Frailty and Outcomes in Older Heart Failure Patients With Ejection Fraction >40%
This study aims to investigate the prevalence of frailty and its association with six-month clinical outcomes in elderly patients with heart failure and left ventricular ejection fraction greater than 40%.
- Conditions
- Frailty Syndrome, Heart Failure and Mildly Reduced Ejection Fraction, Heart Failure and Preserved Ejection Fraction
- Trial name
- NCT07071142
- Where
- 2 sites in Vietnam
- Volunteers
- 301 people
- Sponsor
- Duyen Nguyen Hoang Mai
Heart Failure
A Study Of The Usage Of Statins In A Community Heart Failure Population
Inflammation and fibrosis may be important contributors to worsening heart failure. As well as lowering cholesterol, statins are also known to reduce inflammatory markers such as C-reactive protein which are elevated in severe…
- Trial name
- NCT00795912
- Testing
- Atorvastatin
- Where
- Ireland
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- St Vincent's University Hospital, Ireland
Heart Failure With Reduced Ejection Fraction (HFrEF)
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
- Trial name
- NCT03877237
- Testing
- Dapagliflozin
- Where
- 76 sites in United States, Brazil and 7 more
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
Heart Failure and Reduced Ejection Fraction, Functional Mitral Regurgitation
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
This is a multi-center, prospective, observational study designed to evaluate the impact of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical outcomes post TEER.
- Trial name
- SMARTER-CMR (NCT07131631)
- Testing
- Cardiac MRI
- Where
- 6 sites in United States, Italy
- Volunteers
- 125 people
- Sponsor
- Minneapolis Heart Institute Foundation
Chronic Stable Heart Failure
Qishenyiqi for Ventricular Remodeling After Myocardial Infarction
The effects of Qishenyiqi dripping pill on cardiac remodeling in patients with chronic stable heart failure have not been reported.
- Trial name
- NCT06699407
- Testing
- Qishenyiqi dripping pills
- Where
- 3 sites in China
- Volunteers
- 210 people
- Sponsor
- Qilu Hospital of Shandong University
Systolic Heart Failure
Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations
Rehospitalizations due to exacerbation of chronic heart failure are an important problem for patients suffering from heart failure.
- Trial name
- NCT03764722
- Testing
- Levosimendan
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
- Trial name
- NCT03057977
- Testing
- Empagliflozin
- Where
- 520 sites in United States, Argentina and 18 more
- Volunteers
- 3,730 people
- Sponsor
- Boehringer Ingelheim
Chronic Heart Failure (CHF)
A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care
This low interventional study, whose unique intervention was to measure the blood level of a biomarker called NT-proBNP in chronic heart failure patients daily followed-up by Primary Care Physicians (PCPs) in Europe, assessed if…
- Trial name
- PREFER (NCT02807857)
- Testing
- Standard care
- Where
- 191 sites in Belgium, Croatia and 16 more
- Volunteers
- 1,415 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction, Hyperkalemia
Spanish Study of Hyperkalaemia Incidence and Prognosis in Patients With Heart Failure and Reduced Ejection Fraction
Participant centres and researchers: 20 National Public Health System hospitals. Cardiology specialist physicians Clinical Research Ethics Committee (CREC): Hospital 12 de Octubre, Madrid Main goal: To estimate prevalence and, in…
- Trial name
- SPANIK-HF (NCT04141800)
- Where
- Spain
- Volunteers
- 565 people
- Sponsor
- Spanish Society of Cardiology
Heart Failure, Heart Failure With Reduced Ejection Fraction
Wearable Remote Monitoring of Heart Rate and Respiratory Rate for Heart Failure
The primary objective of this study is to study in heart failure (HF) patients to better assess HF disease state, which can aid in management and improve outcomes.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT04455828
- Testing
- WHOOP strap 3.0
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Heart Failure, Congestive
ACCLAIM - Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy
The purpose of this study is to test the safety and efficacy of the Celacade™ system in reducing the risk of mortality and cardiovascular hospitalizations in patients with chronic systolic heart failure.
- Trial name
- NCT00111969
- Testing
- Celacade™ system
- Volunteers
- 2,016 people
- Sponsor
- Vasogen